Skip to main content
. Author manuscript; available in PMC: 2008 Mar 23.
Published in final edited form as: Biochem Biophys Res Commun. 2007 Jan 23;354(4):955–961. doi: 10.1016/j.bbrc.2007.01.072

Fig 3. Effect of MAPKs inhibitors and TLR2 neutralizing antibody on SpA-induced IL-8 secretion.

Fig 3

HUCL cell were incubated with inhibitors of MAPKs-mediated signal pathways for 30 min prior to the addition of SpA and the induced secretion of IL-8 after 4 h was assessed by IL-8 cytokine ELISA. The inhibitors used include the NF-κB inhibitor isohelenin (IS, 25 μM) and three MAP kinase pathways, SB (p38 MAP kinase inhibitor, 5 μM); SP (JNK inhibitor, 25 μM) and U0126 (ERK inhibitor, 10 μM). Anti-TLR2 antibody (20 μg/ml) was used to block the TLR2 pathway. The data is representative of three individual experiments.